Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression

One of the major limitations to current gene therapy is the low-level and transient vector gene expression due to poorly defined mechanisms, possibly including promoter attenuation or extinction. Because the application of gene therapy vectors in vivo induces cytokine production through specific or...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Human gene therapy Ročník 8; číslo 17; s. 2019
Hlavní autori:	Qin, L, Ding, Y, Pahud, D R, Chang, E, Imperiale, M J, Bromberg, J S
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 20.11.1997
Predmet:	Adenoviruses, Human - genetics Animals Antibodies, Monoclonal - immunology Avian Sarcoma Viruses - genetics Cell Line Cytomegalovirus - genetics DNA, Viral - drug effects Drug Synergism Gene Expression Regulation - drug effects Genes, Reporter Genetic Therapy Genetic Vectors - drug effects Genetic Vectors - immunology Humans Interferon-gamma - immunology Interferon-gamma - pharmacology Lac Operon Mice Mice, Inbred C57BL Moloney murine leukemia virus - genetics Plasmids Promoter Regions, Genetic - drug effects Promoter Regions, Genetic - immunology RNA, Messenger Simian virus 40 - genetics Transformation, Genetic Transgenes - drug effects Tumor Necrosis Factor-alpha - immunology Tumor Necrosis Factor-alpha - pharmacology
ISSN:	1043-0342
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	One of the major limitations to current gene therapy is the low-level and transient vector gene expression due to poorly defined mechanisms, possibly including promoter attenuation or extinction. Because the application of gene therapy vectors in vivo induces cytokine production through specific or nonspecific immune responses, we hypothesized that cytokine-mediated signals may alter vector gene expression. Our data indicate that the cytokines interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) inhibit transgene expression from certain widely used viral promoters/enhancers (cytomegalovirus, Rous sarcoma virus, simian virus 40, Moloney murine leukemia virus long terminal repeat) delivered by adenoviral, retroviral or plasmid vectors in vitro. A constitutive cellular promoter (beta-actin) is less sensitive to these cytokine effects. Inhibition is at the mRNA level and cytokines do not cause vector DNA degradation, inhibit total cellular protein synthesis, or kill infected/transfected cells. Administration of neutralizing anti-IFN-gamma monoclonal antibody results in enhanced transgene expression in vivo. Thus, standard gene therapy vectors in current use may be improved by altering cytokine-responsive regulatory elements. Determination of the mechanisms involved in cytokine-regulated vector gene expression may improve the understanding of the cellular disposition of vectors for gene transfer and gene therapy.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1043-0342
DOI:	10.1089/hum.1997.8.17-2019